<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<article xlink="http://www.w3.org/1999/xlink" dtd-version="1.0" article-type="allergy-and-immunology" lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher">JOHS</journal-id>
<journal-id journal-id-type="nlm-ta">Journ of Health Scien</journal-id>
<journal-title-group>
<journal-title>Journal of HealthCare Sciences</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Journ of Health Scien</abbrev-journal-title>
</journal-title-group>
<issn pub-type="ppub">2231-2196</issn>
<issn pub-type="opub">0975-5241</issn>
<publisher>
<publisher-name>Radiance Research Academy</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">276</article-id>
<article-id pub-id-type="doi">http://dx.doi.org/10.52533/JOHS.2024.40601</article-id>
<article-id pub-id-type="doi-url"/>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Allergy and Immunology</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The Economic and Social Burden of Insulin Resistance in Obesity
</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Abdullah</surname>
<given-names>Marwah Yakoop</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alruwaili</surname>
<given-names>Yousef Musharraf</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alsairra</surname>
<given-names>Munirah Nasser</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Almnaa</surname>
<given-names>Sharifah Abdullah</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mosly</surname>
<given-names>Ahmed Fawzy</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alsuwaidan</surname>
<given-names>Dana Tariq</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Asmari</surname>
<given-names>Rayan Abdulrahman Al</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alsaffar</surname>
<given-names>Hussain Fuad</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alhudaib</surname>
<given-names>Rahaf Saad</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Althobaiti</surname>
<given-names>Ahmed Mohammed</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alhusayni</surname>
<given-names>Hamed Ghazi</given-names>
</name>
</contrib>
</contrib-group>
<pub-date pub-type="ppub">
<day>30</day>
<month>06</month>
<year>2024</year>
</pub-date>
<volume>4</volume>
<issue>6</issue>
<fpage>216</fpage>
<lpage>221</lpage>
<permissions>
<copyright-statement>This article is copyright of Popeye Publishing, 2009</copyright-statement>
<copyright-year>2009</copyright-year>
<license license-type="open-access" href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.</license-p>
</license>
</permissions>
<abstract>
<p>Insulin resistance, a precursor to various metabolic disorders, represents a significant burden when associated with obesity. This detailed examination reveals the multifaceted economic and social impacts of insulin resistance intertwined with obesity. The financial strain is immense, primarily due to the increased prevalence of related conditions such as type 2 diabetes, cardiovascular diseases, and non-alcoholic fatty liver disease. Healthcare costs surge due to the need for continuous management, medications, and treatments, compounded by indirect expenses from reduced productivity and absenteeism. These financial pressures extend beyond individual and healthcare systems, affecting businesses and the broader economy through decreased efficiency and increased disability support costs. Socially, insulin resistance linked to obesity carries profound implications. The stigma associated with obesity often leads to discrimination, adversely impacting the psychological well-being and social status of affected individuals. This stigma can perpetuate workplace bias, hindering career advancement and widening socio-economic disparities. The relationship between obesity and mental health is bidirectional, with insulin resistance exacerbating stress, depression, and anxiety, which further deteriorates the individual__ampersandsign#39;s overall health and social relationships. Effective management of insulin resistance in obesity necessitates a holistic approach. Lifestyle modifications, including dietary adjustments and regular physical activity, are foundational. Medications like metformin and thiazolidinediones are crucial when lifestyle changes are insufficient. Emerging treatments such as SGLT2 inhibitors and gut microbiota modifications offer promising avenues. Addressing comorbid conditions like dyslipidemia and hypertension is vital to reducing overall risk. Patient education is paramount, empowering individuals to take control of their health journey and ensuring a comprehensive understanding of insulin resistance__ampersandsign#39;s physiological and psychosocial aspects. A multidisciplinary approach involving collaboration among healthcare providers is essential. This strategy ensures tailored interventions that address both the physical and emotional dimensions of insulin resistance. As research advances, refining treatment approaches and reducing the social impacts associated with insulin resistance within the obesity framework remains a priority. This comprehensive approach aims to mitigate the broader implications of insulin resistance, fostering a more inclusive and supportive environment for those affected.
</p>
</abstract>
<kwd-group>
<kwd>Behavioral Interventions</kwd>
<kwd> Clinical Management</kwd>
<kwd> Insulin Resistance</kwd>
<kwd> Lifestyle Modifications</kwd>
<kwd> Pharmacological Approaches</kwd>
</kwd-group>
</article-meta>
</front>
</article>